围手术期GLP-1受体激动剂使用与非减重腹壁整形术手术结局:10年回顾性分析
本研究回顾性分析2013年至2023年373例接受腹壁整形术的非减重患者,其中81例使用GLP-1受体激动剂(GLP-1 RA),292例未使用。结果显示GLP-1 RA使用者延迟愈合发生率更高(18.5% vs 7.5%,P=0.0066),但血清肿发生率更低(4.9% vs 14.0%,P=0.032),多因素回归后差异持续存在;感染、脂肪坏死、血肿及GLP-1 RA相关胃肠道副作用无显著差异。结论支持其围手术期安全性,但需警惕潜在愈合延迟。
要点
- GLP-1 RA使用者延迟伤口愈合率显著更高(18.5% vs 7.5%)。
- GLP-1 RA使用者血清肿发生率显著更低(4.9% vs 14.0%)。
- 感染、脂肪坏死、血肿及胃肠道副作用无显著差异。
核心结论
- GLP-1 RA在非减重腹壁整形术患者中总体围手术期安全,但延迟愈合风险增加而血清肿减少。
研究设计与样本
- 回顾性队列研究,纳入2013年1月至2023年1月373例腹壁整形术患者,其中GLP-1 RA使用者81例,非使用者292例。
- 排除既往减重手术或同期疝修补患者,所有患者随访至少1年。
主要发现
- GLP-1 RA使用者2型糖尿病率55.6% vs 29.5%(P=0.01),高血压69.1% vs 52.7%(P=0.04),COPD 17.3% vs 6.5%(P=0.02),前白蛋白22.8±6.6 vs 20.4±7.7 mg/dL(P=0.030)。
- 延迟愈合发生率18.5% vs 7.5%(P=0.0066),血清肿发生率4.9% vs 14.0%(P=0.032),多因素回归后差异持续。
- 感染、脂肪坏死、血肿及GLP-1 RA相关胃肠道副作用无显著差异。
临床怎么用
- 围手术期使用GLP-1 RA的患者应加强伤口愈合监测。
- 可预期血清肿风险较低,但仍需常规引流管理。
局限性
- 回顾性设计,样本量有限,可能存在未校正混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are increasingly used for treatment of patients with type 2 diabetes and obesity because of their metabolic benefits and potential wound-healing properties. However, their perioperative safety in acute surgical settings remains unclear. GLP-1 RAs may alter tissue quality and intensify GLP-1 RA-related side effects. This study was performed to examine postoperative complications and GLP-1 RA-associated adverse effects in nonbariatric patients undergoing panniculectomy. METHODS: The authors conducted a retrospective review of 373 patients who underwent panniculectomy from January of 2013 through January of 2023, including 81 GLP-1 RA users and 292 nonusers. Patients with previous bariatric surgery or concomitant hernia repair were excluded due to the added complexity of mesh placement and altered tissue planes, which could confound wound-healing outcomes. 1 All participants had at least 1 year of follow-up. Baseline demographics, nutritional markers, and GLP-1 RA therapy duration were recorded. Logistic regression was performed to adjust for confounders when comparing complications and adverse effects. RESULTS: GLP-1 RA users had higher rates of type 2 diabetes (55.6% versus 29.5% [ P = 0.01]), hypertension (69.1% versus 52.7% [ P = 0.04]), and chronic obstructive pulmonary disease (17.3% versus 6.5% [ P = 0.02]), along with elevated prealbumin levels (22.8 ± 6.6 versus 20.4 ± 7.7 mg/dL [ P = 0.030]). Analyses showed a greater incidence of delayed wound healing (18.5% versus 7.5% [ P = 0.0066]) but lower seroma rates (4.9% versus 14.0% [ P = 0.032]) in GLP-1 RA users. These differences persisted on multivariable regression. No significant differences were noted in infection, fat necrosis, hematoma, or GLP-1 RA-related gastrointestinal side effects. CONCLUSIONS: GLP-1 RAs demonstrate promise in chronic wound care. Their use was correlated with increased incidence of delayed wound healing but fewer seromas in acute surgical settings. Overall, these findings support their perioperative safety, but vigilant monitoring for potential wound-healing delays is advised.
引用
- Koenig ZA, Rashid S, Hobbs GR, et al. Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis. Plast Reconstr Surg. 2025. PMID: 40875227. doi:10.1097/PRS.0000000000012405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。